[{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Cipla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cipla \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cipla \/ Undisclosed"},{"orgOrder":0,"company":"The HIV Netherlands Australia Thailand Research Collaboration","sponsor":"Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The HIV Netherlands Australia Thailand Research Collaboration","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The HIV Netherlands Australia Thailand Research Collaboration \/ Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"The HIV Netherlands Australia Thailand Research Collaboration \/ Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare"},{"orgOrder":0,"company":"St Stephen's AIDS Trust","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"St Stephen's AIDS Trust","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St Stephen's AIDS Trust \/ ViiV Healthcare","highestDevelopmentStatusID":"11","companyTruncated":"St Stephen's AIDS Trust \/ ViiV Healthcare"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"PPD | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ PPD | GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ PPD | GSK"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ GSK","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ GSK"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"ViiV Healthcare","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"ViiV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ViiV Healthcare \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"ViiV Healthcare \/ Pfizer Inc"},{"orgOrder":0,"company":"Therapeutic Concepts","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Therapeutic Concepts","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Therapeutic Concepts \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Therapeutic Concepts \/ Undisclosed"},{"orgOrder":0,"company":"Mills Clinical Research","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Mills Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mills Clinical Research \/ ViiV Healthcare","highestDevelopmentStatusID":"1","companyTruncated":"Mills Clinical Research \/ ViiV Healthcare"},{"orgOrder":0,"company":"University of Miami","sponsor":"Medtronic Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Oncology","graph2":"Phase I","graph3":"University of Miami","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Miami \/ Medtronic plc","highestDevelopmentStatusID":"6","companyTruncated":"University of Miami \/ Medtronic plc"},{"orgOrder":0,"company":"McGill University Health Centre Research Institute","sponsor":"ViiV Healthcare | CIHR Canadian HIV Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"McGill University Health Centre Research Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McGill University Health Centre Research Institute \/ ViiV Healthcare | CIHR Canadian HIV Trials Network","highestDevelopmentStatusID":"11","companyTruncated":"McGill University Health Centre Research Institute \/ ViiV Healthcare | CIHR Canadian HIV Trials Network"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"IMPAACT | Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Mental Health | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ IMPAACT | Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Mental Health | ViiV Healthcare","highestDevelopmentStatusID":"7","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ IMPAACT | Gansu Provincial Maternal and Child Health Care Hospital | National Institute of Mental Health | ViiV Healthcare"},{"orgOrder":0,"company":"Viatris","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ ViiV Healthcare"},{"orgOrder":0,"company":"Viatris","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Abacavir","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Viatris \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Viatris \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ ViiV Healthcare","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ ViiV Healthcare"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayside Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayside Health \/ Undisclosed"},{"orgOrder":0,"company":"Neuroscience Trials Australia","sponsor":"Macquarie University | Westmead Hosptial | Calvary Health Care Bethlehem | The University of Sydney - Brain and Mind Centre","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Neurology","graph2":"Phase II","graph3":"Neuroscience Trials Australia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuroscience Trials Australia \/ Macquarie University | Westmead Hosptial | Calvary Health Care Bethlehem | The University of Sydney - Brain and Mind Centre","highestDevelopmentStatusID":"8","companyTruncated":"Neuroscience Trials Australia \/ Macquarie University | Westmead Hosptial | Calvary Health Care Bethlehem | The University of Sydney - Brain and Mind Centre"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"||Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ ViiV Healthcare"}]
Find Clinical Drug Pipeline Developments & Deals for (+/-)-Abacavir
Details :
Triumeq PD-Generic is a fixed dose combination of abacavir, dolutegravir, and lamivudine. It is indicated for the treatment of HIV-1 infection in pediatric patients.
Details :
Triumeq PD-Generic is a fixed dose combination of abacavir, dolutegravir, and lamivudine. It is indicated for the treatment of HIV-1 infection in pediatric patients.
Details :
Abacavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glioma.
Details :
The fixed-dose combination of abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg tablets for oral suspension is indicated for the treatment of HIV-1 infection in paediatric patients weighing at least 6 kg.
Details :
Edurant (rilpivirine) is a HIV-1 specific, nonnucleoside reverse transcriptase inhibitor (NNRTI). It is being evaluated for the treatment of HIV-1 infection in children weighing 10 kg or more.
Details :
The ‘4-in-1’ combination contains an antiretroviral combination of Abacavir, as an alternative first-line regimen for infants and young children with HIV – in the form of granule-filled capsules.
Details :
In addition, a supplemental new drug application (sNDA) has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 (HIV-1) can be prescribed this medicine to 25kgs from 40kgs.
Details :
ViiV Healthcare enables generic versions of dolutegravir to be manufactured and sold royalty-free for the treatment of children living with HIV in all least-developed, low-income, lower-middle-income and sub-Saharan Africa countries, also some upper-midd...
Details :
New dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine to extend its current approval for Triumeq for younger children living with HIV.
Details :
Abacavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Reset All
